Tuesday, 14 January 2025

A Rare Case: Treatise on Classical Hodg-kin Lymphoma-Mixed Cellularity Stage 3B with Vincristine-Induced Peripheral Neuropathy | Chapter 12 | Medical Research and Its Applications Vol. 6

Classical Hodgkin lymphoma is a lymphatic system cancer that affects 2-1 cases per 100,000 people annually in developed nations. We report a unique case of vincristine-induced peripheral neuropathy associated with acute pan-creatitis in a 16-year-old male patient suffering from classical Hodgkin lym-phoma (CHL) with the primary symptom of bilateral cervical lymphadenopathy. However, upon diagnosis, this youngster was found to have cervical lympho-ma, which differs from the other symptoms of the disease. Diagnosed in Feb-ruary 2023 with CHL, the patient was stratified based on the Ann Arbor staging of Hodgkin lymphoma guidelines by the European Network for Pediatric Hodg-kin Lymphoma (EURONET-PHL). Laboratory and physical examination con-firmed the clinical conditions of peripheral neuropathy and acute pancreatitis, which are adverse effects of chemotherapy, which were managed with IV Pipe-racillin Tazobactam (100 mg/kg) and opioid medications. The European Net-work-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) developed the standard protocol for the first-line therapy of Hodgkin lymphoma in children. Vincristine-induced neuropathy was treated with Morphine (10 mg orally) and Gabapentin (300 mg) was used to provide analgesia. His chemotherapy in-volved two cycles of an OEPA regimen, in accordance with guidelines for the treatment of CHL, and improved clinically. This case report is being offered to clinically enlighten people about the early diagnosis, treatment of CHL and adverse effects of the vincristine drug used in chemotherapy in pediatric pa-tients.

 

Author(s)details:-

 

Krithika Sri J. B.
Gleneagles Global Hospital, Chennai, Tamil Nadu, India.

 

Priyanka N.
Gleneagles Global Hospital, Chennai, Tamil Nadu, India.

 

Please See the book here :- https://doi.org/10.9734/bpi/mria/v6/282

No comments:

Post a Comment